Replimune's drug for advanced skin cancer fails to win FDA nod again - Reuters
Replimune's drug for advanced skin cancer fails to win FDA nod again Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Notable Quotes
"the company has no choice but to eliminate jobs and substantially scale back its U.S.-based manufacturing operations as a result of the decision."
— Sushil Patel , Executive
"decision on Tudriqev makes 'one less competitor' in the near-term for Iovance’s Amtagvi."
— Andrew Tsai , Executive
"the decision on Tudriqev makes 'one less competitor' in the near-term for Iovance’s Amtagvi."
— Andrew Tsai , Executive
Key People
Locations
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQV0xhbE5EbkRDa2l2OEdTdkhHRzlZU1cwdUM4bWt6ZGVTTWNIeFFUdHhDaW9SOHBiM3A3eV9VVTZoNXlRM0pNSk5adXJ1Vkw1SDZqSWI5aGlfT3B1VThsV21acFBVUU1RTE9oZXNSbHRMUlZTSzhNTGdXQTJELUgycm1QM0d5cGdQdlNicURjZEZ5LXVxa2t6MWh0aEI2N1o0UVM1X2VxMDAtb0t1T0pzSFdNTQ?oc=5" target="_blank">Replimune's drug for advanced skin cancer fails to win FDA nod again</a> <font color="#6f6f6f">Reuters</font>
The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.
The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.
The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.
The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.
The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.
Similar Stories
Related coverage based on topic and tags
'What terminal cancer has taught me about life'
A Gloucestershire man with terminal cancer shares the life lessons he wishes he'd learned sooner.
October 10, 2026 at 06:16 AMBoots has a new owner: Three ways it could affect you
The stalwart of Britain's High Street has been sold to a Canadian billionaire family. What will that mean for you?
October 9, 2026 at 11:01 PMUS FDA approves Asahi Kasei's drug for persistent herpes infections - Reuters
US FDA approves Asahi Kasei's drug for persistent herpes infections Reuters
October 9, 2026 at 06:01 PMReport highlights flaws in ADHD and autism care
There is a risk of people being over-diagnosed with ADHD and autism, an official review in England has found.
October 9, 2026 at 01:52 PMHumana surges after topping 2027 Medicare star ratings - Reuters
Humana surges after topping 2027 Medicare star ratings Reuters
October 9, 2026 at 01:33 PMTeva wins FDA approval for monthly schizophrenia injection Weltruza - Reuters
Teva wins FDA approval for monthly schizophrenia injection Weltruza Reuters
October 9, 2026 at 11:47 AM